CWM
REGN icon

Catamount Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Catamount Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4,275
Closed -$1.66M – 181
2016
Q3 		$1.66M Buy
+4,275
New +$1.71M 1.42% 16

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Catamount Wealth Management's REGN Position: Q4 2016 in Review

Catamount Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2016, closing a stake of 4,275 shares — an estimated $1.66M sold.

Catamount Wealth Management first reported a position in REGN in Q3 2016 and held it in 1 quarter. The position peaked at $1.66M in Q3 2016. 576 funds tracked by Wall St. Rank hold REGN as of Q4 2016.

  • Catamount Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Catamount Wealth Management sold 4,275 Regeneron Pharmaceuticals shares in Q4 2016, an estimated $1.66M.
  • Catamount Wealth Management first reported a position in Regeneron Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Catamount Wealth Management's Regeneron Pharmaceuticals position peaked at $1.66M in Q3 2016.
  • 576 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2016.

Based on Catamount Wealth Management's 13F filing for Q4 2016, filed 14 Feb 2017.